Background/Aims: Vascular endothelial growth factor (VEGF) is a key molecule in the regulation of both angiogenesis and vascular permeability. However, it is known that overproduction of VEGF induces abnormal blood vessel formation and these vessels cause several disease pathologies, such as diabetic retinopathy. The purpose of this study was to find novel vasoactive compounds which have different properties from VEGF. Methods/Results: We screened a natural product library using a co-culture angiogenic assay of endothelial cells and fibroblasts. By focusing on morphological changes of endothelial cells, we isolated the novel compounds vestaine A 1 and vestaine B 1 from the cultured broth of an actinomycete strain, Streptomyces sp. SANK 63697. Vestaine A 1 enhanced tube formation of endothelial cells in Matrigel and suppressed cell death induced by serum deprivation. Vestaine A 1 activated both MEK1/2 and PI-3 kinase pathways independently of the VEGF pathway in a dose-and time-dependent fashion. Finally, vestaine A 1 potently suppressed VEGF-induced vascular permeability both in vitro and in vivo. Conclusion: Vestaine A 1 has the potential to exhibit both pro-angiogenic and anti-permeability properties, and would therefore be useful for therapeutic treatment for abnormal vascular permeability-related diseases.
Introduction
Blood vessels are extended throughout the body, deliver nutrients and oxygen into all tissues, and take away waste products. To maintain vascular integrity, our body constantly produces new vessels through angiogenesis, and then enhances stabilization of such newly formed vessels through vessel maturation. In adults, this process is tightly regulated by the coordinated function among pro-angiogenic factors, anti-angiogenic factors, extracellular matrix production, degradation, and so on [1] .
Angiogenesis is a process critical to the formation of new vessels and maintenance of vessel integrity. However, it is known that excess angiogenesis induces fragile vessel formation and these vessels are problematic in many clinical settings, causing complications such as diabetic retinopathy and cerebral hemorrhage. In the retinas of diabetic patients, the decrease in blood flow and thrombosis formation induces a hypoxic condition, and continuous hypoxia induces abrupt new vessel formation. Such abruptly formed vessels are structurally fragile, leaky, poor in oxygen delivery, and prone to cause hemorrhage. These properties cause further dysfunction in diabetic retinae, leading to blindness [2] . At the acute phase of stroke, fragile new blood vessels are also induced by ischemia at the distal cite of the thrombus in the brain. Thrombolytic drugs such as recombinant thrombin are useful for treating the condition. However, adaptation of thrombolytic therapy is limited because reperfusion by thrombolysis sometimes causes hemorrhaging from the fragile vessels [3, 4] . Additionally, leaky vessels are also observed in tumors. The highly hypoxic condition in solid tumors induces formation of fragile vessels. These structurally abnormal vessels are leaky and poor in oxygen delivery, resulting in a decrease in anti-tumor drug delivery, and are one of the causes of resistance to radiation therapy [5] . Therefore, a treatment to eliminate the fragile vessels by suppressing excess angiogenesis or enhancing vessel maturation would be useful for treating these clinical conditions. Vascular endothelial growth factor (VEGF) is a key molecule of angiogenesis and also plays a critical role in abnormal vessel formation. In several clinical settings, overproduction of VEGF has been observed in lesions where abnormal vessel formation causes problems [6] [7] [8] [9] . Recently, anti-VEGF antibodies have been approved to treat eye diseases such as agerelated macular degeneration and cancer, and show steady efficacy [1, 10, 11] . Therefore, medicines which accomplish abnormal vessel elimination through mechanisms different from anti-VEGF therapy would be useful to provide other options for patients showing resistance or insufficient response to the anti-VEGF therapy.
In this study, we focused on identifying novel vasoactive compounds with a mechanism of action different from VEGF's action. We screened a natural product library using a coculture assay of endothelial cells with fibroblasts and found two novel compounds, vestaine A 1 and vestaine B 1 . We also confirmed that vestaine A 1 possesses both pro-angiogenic and anti-vascular permeability activity, which suggests the possibility that vestaine A 1 is useful for therapeutic treatment. 1 H NMR spectra were recorded on a JEOL GSX 500 -NMR spectrometer, and chemical shifts are given in ppm (δ) from tetramethylsilane as an internal standard. The spectral splitting patterns are designated as follows: s, singlet; d, doublet; dd, doublet of doublets; t, triplet; q, quartet; m, multiplet. The mass spectra were recorded on a JEOL LC mate spectrometer (ESI).
14-Methylpentadec-1-en-3-ol (4)
To a cooled 10-Bromo-1-deceanol (1) (14 g, 50 mmol) at -10°C was added a solution of 0.1 mol/L lithium tetrachloro cuprate (II) in THF (50 ml, 5.0 mmol) and 1 mol/L isobutyl magnesium bromide solution in THF (150 ml, 150 mmol) were added under an atmosphere of nitrogen. After being stirred at that temperature for 2 h, the reaction was quenched by addition of sat. NH 4 Cl solution and extracted with EtOAc. The extract was washed with brine, dried over Na 2 SO 4 , and concentrated under reduced pressure to afford 2 as a colorless oil.
A mixture of 2 (50 mmol) and dimethyl sulfoxide (DMSO) (17.8 ml, 250 mmol) in dichloromethane (100 ml) was cooled to 0°C under an atmosphere of nitrogen. To the reaction mixture, triethylamine (27.9 ml, 200 mmol) and Py•SO 3 (19.9 g, 125 mmol) were added at that temperature and stirred for 2 h. After being stirred at room temperature for 30 min., the reaction mixture was concentrated. The resulting residue was diluted with water and extracted with hexane. The extract was washed with brine, dried over Na 2 SO 4 , and concentrated under reduced pressure to afford 3 as a colorless oil.
A solution of 3 (50 mmol) in THF (150 ml) was cooled to 0°C under atmosphere of nitrogen. To the reaction mixture, 1 mol/L vinyl magnesium bromide solution in THF (65 ml, 65 mmol) was added at that temperature. After being stirred at that temperature for 30 min, the reaction was quenched by the addition of sat. NH 4 Cl solution and extracted with EtOAc. The extract was washed with brine, and dried over Na 2 SO 4 . After removing the solvent, the resulting mixture was purified by flush column chromatography on silica gel with hexane/EtOAc (4:1, v/v) as eluent to give 4 (10.3 g, 86% 3 steps) as a colorless oil. 
14-Methylpentadec-1-en-3-one (5)
A mixture of 14-methylpentadec-1-en-3-ol (4) (6.0 g, 25 mmol) and MnO 2 (75 g) in chloroform (150 ml) was stirred at 50°C for 5 h. To a reaction mixture, MnO 2 (45 g) was added and stirred for 1 day. The mixture was filtered through a celite pad and the resulting filtrate was concentrated. The residue was diluted with chloroform (150 ml). To a reaction mixture, MnO 2 (90 g) was added and stirred for 3 days at room temperature. After being filtered through a celite pad, the resulting filtrate was concentrated to afford 5 (2.5 g, 42%) as a colorless oil. 
1,2-Dibromo-14-methylpentadecan-3-one (6)
To a cooled solution of 14-methylpentadec-1-en-3-one (5) (2.5 g, 10.5 mmol) in dichloromethane (100 ml), a solution of bromine (0.60 ml, 11.5 mmol) in dichloromethane (5 ml) was added at 0°C. The reaction was quenched by addition of sat. Na 2 SO 4 solution and extracted with dichloromethane. The extract was washed with brine, dried over Na 2 SO 4 , and concentrated under reduced pressure to give 6 (3.5 g, 84%) as a colorless oil. 
Methyl N-acetyl-S-(2-bromo-14-methyl-3-oxopentadecyl)-L-cysteine (8)
To a solution of 1,2-dibromo-14-methylpentadecan-3-one (6) (3.5 g, 8.79 mmol) in THF (100 ml), TEA (2.7 ml, 19.3 mmol) was added at 0°C under atmosphere of nitrogen. After being stirred for 15 min at that temperature, N-acetyl-L-cysteine (1.6 g, 9.67 mmol) was added to the reaction mixture and stirred for 1 h. The reaction mixture was warmed up to room temperature and stirred for 1 h. The reaction was quenched by addition of 1 N HCl (30 ml) at 0°C and extracted with ethyl acetate. The extract was washed with brine, dried over Na 2 SO 4 and concentrated under reduced pressure to give 7 as a colorless oil.
To a solution of 7 (8.79 mmol) in THF/MeOH (100/30 ml), 2 mol/L trimethylsilyldiazomethane in ether solution (8.0 ml, 16 mmol) was added and stirred for 1 h. After removing the solvent, the residue was purified by flush column chromatography in silica gel with hexane/EtOAc (From 100/0 to 0/100, v/v) as eluent to give 8 (1.5 g, 35%, 2 steps) as a colorless oil. 
03 mmol) in THF (30 ml), 2 mol/L dimethylamine in THF solution (15 ml, 30 mmol) was added at 0°C under an atmosphere of nitrogen. The reaction mixture was stirred for 1 day with gradual warming up to room temperature. The reaction was quenched by water and extracted with ethyl acetate. The extract was washed with brine, dried over Na 2 SO 4 , and concentrated under reduced pressure to give 9 as a colorless oil.
A mixture of 9 (3.03 mmol) and MeI (0.94 ml, 15.3 mmol) in CH 3 CN (14 ml) was irradiated by microwave reactor at 90°C for 1.5 h. The reaction mixture was concentrated to afford 10 as a colorless oil.
A mixture of 10 and 3 N HCl (20 ml) was heated 80°C for 3 h with stirring. After concentrated the reaction mixture, CH 3 CN was added to the residue and dissolved. After removing the unsolved material by filtration, the mother liquid was concentrated and purified by reverse phase HPLC (Nacalai cosmosil 15C 18 -MS-II, CH 3 CN/water = From 1/99 to 90/10, v/v) as eluent to give vestaine A 1 (synthesic-1) (27 mg, 2%, 3 steps) as a colorless amorphous solid. 
Cell culture
Human umbilical vein endothelial cells (HUVECs) and normal human dermal fibroblasts were obtained from KURABO. HUVECs were cultured in collagen-I coated culture dishes in HuMedia-EG2. Cells were used between passage 3 and 7. Fibroblasts were cultured in culture dishes in HuMedia-EG2 and used between passage 3 and 10. All cells were incubated at 37°C under a humidified atmosphere of 5% CO 2 in air.
Establishment of EGFP-labeled HUVEC (GFP-HUVEC)
HUVECs were seeded at 5 × 10 5 cells per dish in collagen-I coated 10 cm dishes with 10 ml of VascuLife EnGS Comp Kit. After 1 day, the medium was replaced with ice-cold HuMedia-EG2, and infected with 250 μl of Cignal-Lenti Positive Control (GFP) supplemented with 4 μg/ml hexadimethrine bromide. After the second passage, the cells were cultured using HuMedia-EG2. The infected cells were passaged four times, and stored using CELLBANKER-1 at -80°C.
A co-culture assay of endothelial cells with fibroblasts: VS-G assay
Fibroblasts were seeded in 96-well black clear bottom plates (Corning). GFP-HUVECs were seeded at 7.5 × 10 3 cells onto the confluent fibroblasts' feeder layers in HuMedia-EG2. In the case of co-treatment with vestaine A 1 and VEGF, the number of GFP-HUVECs was 3.5 × 10 3 cells. After adhesion of GFP-HUVECs to the fibroblasts' layers, cells were washed by assay medium (M199, 0.5% FBS), cultured broths or test compounds in assay medium were added, and incubated at 37°C for 3 days. Cell images were captured using an In Cell Analyzer 6000 (GE) or ImageXpress ULTRA (Molecular Devices). The value of area covered by GFP-HUVECs was analyzed using IN Cell Investigator 1.6 or MetaXpress and its value was used as the in vitro activity. The wells treated with 0.25% DMSO in assay medium were used as a negative control (0% activity), and the wells treated with 50 ng/ml of VEGF were used as a positive control (100% activity). In vitro activity was calculated as below:
In vitro
For graphs, in vitro activity was shown using the number of maximum area value of treatment with vestaine A 1 as a base of 100 and half maximal effective concentration (EC 50 ) was calculated using SAS System Release 9.2 (SAS institute Institute Inc.).
Matrigel tube formation assay
Growth factor reduced Matrigel was added to cold 24-well plates, and incubated at 37°C for more than 30 min. After test compounds were added, HUVECs were seeded at 1 × 10 5 cells onto the Matrigel, and incubated for 37°C. After 24 h, images of the cells were captured under microscopy.
Measurement of cell survival activity
Confluent HUVECs were treated with test compounds in serum deprived assay medium (M199, 0.5% FBS) at 37°C for 24 h. The medium was replaced with 100 μl of fresh assay medium containing Alamar blue reagent, and incubated at 37°C for 3 h. The fluorescence was measured at 530 nm excitation wavelength and 590 nm emission wavelength. The wells treated with 0.25% DMSO in assay medium were used as a negative control (0% survival), and the wells cultured in growth medium (HuMedia-EG2) were used as a positive control (100% survival). Survival activity was calculated as below:
Cell survival activity (
Western blotting
HUVECs were seeded into collagen-I coated plates, and grown to confluence. HUVECs were starved in M199 containing 0.5% FBS for 3 h. After pre-treatment with an inhibitor for 15 min, the cells were treated with vestaine A 1 for various amounts of time. They were lysed in lysis buffer (20 mM Tris-HCl [pH 7.4], 150 mM NaCl, 1 mM EDTA, 0.5% Triton X-100, Complete EDTA-free, and phosphatase inhibitor cocktail) on ice for 15 min and centrifuged at 15,000 rpm for 15 min. The supernatants were collected as samples, mixed with NuPAGE® LDS Sample Buffer (Thermo Fisher Scientific Inc), and boiled for 5 min. Proteins were separated by SDS-PAGE, transferred to PVDF membrane (Millipore), blocked with BlockACE (DS Pharmabiomedical) in phosphate-buffered saline, pH 7.4, and 0.05% Tween 20 for 1 h at room temperature, and incubated overnight at 4°C with primary antibody (1:1000). The membranes were incubated with diluted horseradish peroxidase-linked secondary antibodies (1:5000) for 1 h at room temperature, and then antibodies were detected using ECL prime Western Blotting Detection Reagents.
In vitro endothelial permeability assay
Endothelial barrier function was evaluated by measuring transendothelial electric resistance (TER) using an xCELLigence Real Time Cell Analyzer (RTCA) DP instrument (ACEA Bioscience) and by referencing the manufacturer's instructions and the previous paper [12] . HUVECs were seeded into the collagen-I coated wells of E-plate VIEW 16 (16 electrodes) and incubated for 24 h. After washing the electrodes with new medium, HUVECs were treated with VEGF (100 ng/ml) for 3 h. Test compounds were added to the E-plate VIEW 16 and the impedance termed "cell index (CI)" was continuously measured in the following hours. The wells cultured in growth medium (vehicle -) were used as vehicle control, and the wells treated with VEGF (VEGF -) were used as VEGF only. For analysis, impedance values were normalized to each time point average impedance value of vehicle control as baseline normalized impedance (termed "baseline 
In vivo vascular leakage assay
All experimental procedures were performed in accordance with the in-house guidelines of the Institutional Animal Care and Use Committee of Daiichi Sankyo Co., Ltd. Six to seven week old C57/BL6 mice were injected intraperitoneally with saline or test compounds. After 4 h, 100 μl of 1.5% Evans Blue was injected into their jugular veins. As soon as the mice were anesthetized with isoflurane inhalation, VEGF (60 ng per ear) was administrated intradermally into ears and circulated for 30 min. The mice were euthanized
Results

Vestaine A 1 and vestaine B 1 as novel vasoactive compounds
To obtain novel vasoactive compounds which possess different properties from VEGF, we conducted a screening in a well-established co-culture assay of endothelial cellsfibroblasts (VS-G assay). In the VS-G assay, GFP-labeled human umbilical vein endothelial cells (GFP-HUVECs) were seeded onto feeder fibroblasts, treated with test samples for 3 days, and morphological changes of GFP-HUVECs were analyzed by image analyzer. VEGF treatment readily induces a tube-like structure change of endothelial cells, reflecting strong angiogenic activity of VEGF (Fig. 1A) . In the screening for the compounds which induced different morphological changes of endothelial cells from VEGF, we tested about 13,000 culture extracts of the microorganisms. As a result, we found the unique island-shaped morphological change in the extract of an actinomycete strain, Streptomyces sp. SANK 63697 (Fig. 1A) . From the broth of the SANK 63697, we isolated two active compounds, vestaine A 1 and vestaine B 1 . Phsico-chemical analysis revealed that vestaine A 1 and vestaine B 1 are novel compounds which consist of N-acetylcystein and alkyl chain moieties (Fig. 1B) . Details of the fermentation, isolation, physico-chemical properties, and structural elucidations of vestaines were reported independently [13] . The difference between vestaine A 1 and vestaine B 1 is the length of their alkyl chains and the activity of vestaine A 1 and B 1 in VS-G assay was approximately the same potent. The purified vestaine A 1 dose-dependently induced islandshaped morphology in the VS-G assay (Fig. 1C) . Based on the identified structure information of natural vestaine A 1 (natural-1), the total synthesis of vestaine A 1 (synthetic-1) was conducted (Fig. 2) . We confirmed that synthesized vestaine A 1 (synthetic-1) showed equal potency as purified vestaine A 1 (natural-1) in the VS-G assay (Fig. 1C) . Herafter, we used the synthetic-1 as a representative active compound from SANK 63697 for following biological assays. In the VS-G assay, the effect of VEGF is saturated at 50 ng/ml, so we hypothesized that no additive effect was observed by co-treatment with the compound which acts VEGF pathway and 50 ng/ml of VEGF. In fact, teleocidin B 3 , which activates general pathways as a tumor promoter and induced a tube-like morphology in the VS-G assay (Fig. 1A) , showed no additive effect by co-treatment with VEGF (Fig. 1D) . Co-treatment with vestaine A 1 and VEGF showed synergistic effects in the VS-G assay ( Fig. 1D and 1E ). These results supported that vestaine A 1 affected endothelial cells via different mechanisms from the VEGF pathway.
The existence of trimethylamine in vestaine A 1 raised the possibility that vestaine A 1 is prone to be degraded around the site and the consequent metabolites exert its function in the VS-G assay. To examine this possibility, the possible metabolite of vastaine A 1 , compound-b and compound-c, were synthesized and analyzed in the VS-G assay (Table 1) . Neither compound-b nor compound-c showed the activity. On the other hand, compound-a, which conserved most of the chemical structure of vestaine A 1 , maintained the activity ( Table 1 ), suggesting that all of the components of vestaine A 1 are related to its activity and vestaine A 1 itself is the active body. Collectively these data indicate that vestaines are new potent vasoactive compounds derived from natural product.
Vestaine A 1 induced endothelial tube formation and promoted cell survival
Then the biological effects of vestaines on endothelial cells were further analyzed. Since the VS-G assay contained both endothelial cells and fibroblasts, we analyzed direct effects of vestaine A 1 on endothelial cells using a Matrigel tube formation assay and survival assay. In the Matrigel tube formation assay, vestaine A 1 strongly induced tight tube-like structure (Fig. 3A) . In the cell survival assay, vestaine A 1 dose-dependently suppressed serum-deprivation induced cell death at the equivalent level as VEGF and bFGF, two major survival factors of endothelial cells (Fig. 3B) . These results indicate that vestaine A 1 directly affects endothelial cells and has the potential to induce tube formation and promote endothelial survival, two features of angiogenesis. 
Vestaine A 1 induced both ERK and Akt signals in endothelial cells via a VEGFR2-independent pathway
Then, we analyzed signaling pathways activated by vestaine A 1 in endothelial cells. It is well-known that many vasoactive factors such as VEGF, bFGF, and angiopoietin-1 exert their various vascular activities through the activation of extracellular signal-regulated kinase (ERK) and protein kinase B (Akt) in endothelial cells [14, 15] . ERK is known to be activated in the stage of proliferation and angiogenesis and Akt is mainly required for maintenance and quiescence of endothelial cells [16] . To evaluate the effect of vestaine A 1 on ERK and Akt pathways, HUVECs were treated with different doses of vestaine A 1 for different intervals and the level of the phosphorylated ERK or Akt was determined using Western blotting. Vestaine A 1 dose-dependently induced both ERK and Akt phosphorylation (Fig. 4A) . The effective concentration was shown to be similar to that in the VS-G assay. The maximum activation was observed at 10 min after treatment (Fig. 4B) , which indicates that vestaine A 1 induces ERK and Akt phosphorylation within a relatively short period of time. ERK and Akt phosphorylation was inhibited by MEK1/2 inhibitor (PD98059) or PI3-K inhibitor (LY294002), respectively (Fig. 4C) , suggesting that vestaine A 1 activates ERK via a MEK1/2- Table 1 . In vitro activity in VS-G assay of vestaine A 1 derivatives. Vestaine A 1 derivatives were evaluated by VS-G assay. EC 50 was calculated using the number of maximum area value of vestaine A 1 as a base of 100 and shown the value in two or three independent study 
dependent pathway and Akt via a PI3-kinase-dependent pathway. A VEGFR2 inhibitor didn't affect the phosphorylation status of ERK and Akt induced by vestaine A 1 (Fig. 4C) . Furthermore, VEGF strongly induced VEGFR2 and ERK phosphorylation but weakly induced Akt phosphorylation, whereas vestaine A 1 didn't induce VEGFR2 phosphorylation and strongly induced both ERK and Akt phosphorylation (Fig. 4D) . These results indicate that the strengths and patterns of ERK and Akt pathway activation induced by vestaine A 1 are different from that of VEGF, further supporting the possibility that vestaine A 1 could exert a different vasoactive activity from VEGF.
Vestaine A 1 suppressed VEGF-induced vascular leakage
To further elucidate the difference between vestaine A 1 and VEGF action on endothelial cells, we focused on the effects on vascular permeability regulation. VEGF has been known as not only a pro-angiogenic factor but also as a potent stimulator which increases vascular permeability [17, 18] . First, we investigated the effect of vestaine A 1 on barrier function by measuring the impedance using a xCELLigence real-time cell analyzer DP system. Single treatment with vestaine A 1 elevated HUVEC impedance (Fig. 5A) . VEGF strikingly decreased the HUVEC impedance, and addition of vestaine A 1 completely recovered the impedance decrease (Fig. 5A) . These results suggest that vestaine A 1 enhances endothelial barrier function in vitro and also can antagonize the increase of vascular permeability induced by VEGF.
Next, we tested the effect of vestaine A 1 on vascular permeability in vivo. Vascular permeability was assessed by measuring Evans Blue dye leakage from ear vessels in mice. VEGF strongly induced leakage of Evans Blue dye, and pretreatment of vestaine A 1 clearly suppressed vascular permeability induced by VEGF (Fig. 5B) . These results suggest that vestaine A 1 also has a suppressive effect on vascular permeability in vivo.
Discussion
Angiogenesis is a process critical to maintaining blood vessel integrity, but excess angiogenesis results in the formation of fragile vessels which are largely dysfunctional and cause various problems in several clinical settings. VEGF is a key angiogenic factor and permeability mediator. Excess angiogenesis and the resulting permeability increase triggered by VEGF overproduction is reported as one of the causes of several disease pathologies, such as retinopathy and cerebral hemorrhage. In this context, a treatment which supports angiogenesis, but can antagonize the undesirable effects of VEGF would be useful for treating diseases caused by fragile blood vessels. In the present study, we screened natural products and identified vestaine A 1 and vestaine B 1 as vasoactive compounds. Vestaine A 1 showed the intriguing properties of having both pro-angiogenic and anti-permeability activity.
Vestaine A 1 showed several properties as a pro-angiogenic factor, such as tube formation enhancement on Matrigel (Fig. 3A) , promotion of cell survival upon serum deprivation (Fig. 3B) , and ERK and Akt activation (Fig. 4A, 4B , 4C, and 4D). However, these effects are supposed to be caused by the signaling pathways different from VEGF. In the VS-G assay, vestaine A 1 promoted an island-shaped morphological change of endothelial cells, whereas VEGF induced a tube-like morphology ( Fig. 2A) . Recent papers have demonstrated that the difference in the pattern of morphological change in the co-culture assay reflects the difference in the modes of function of vasoactive compounds [19] [20] [21] . In agreement with the above papers, although teleocidin B 3 which induced a tube-like morphology in the VS-G assay had no additive effect by co-treatment with VEGF, co-treatment with vestaine A 1 and VEGF showed synergistic effects in the VS-G assay ( Fig. 1D and 1E) . Furthermore, vestaine A 1 induced ERK and Akt phosphorylation without affecting the VEGF pathway (Fig. 4C) . These findings strongly suggest that vestaine A 1 works on endothelial cells via a different pathway from VEGF and has different biological effects on endothelial cells from VEGF. Actually we confirmed that in permeability control vestaine A 1 functioned to antagonize VEGF ( Fig. 5A and 5B). The determination of mechanism of action of vestaine A 1 , especially identification of target molecules, would provide new insight into the understanding of angiogenesis regulation. Further examination is needed to specify the mechanism.
Vestaine A 1 dramatically enhanced barrier function of endothelial cells both in vitro (Fig. 5A ) and in vivo (Fig. 5B) , indicating that vestaine A 1 would work not only to induce angiogenesis but also to enhance vessel maturation. Vascular permeability regulation is critical to maintaining proper transportation of nutrition or chemicals in tissues and to regulate inflammation. VEGF is a well-known inducer of vascular permeability. Excess VEGF induces fragile and leaky vessels with low adhesion molecule expression and poor coverage by mural cells, and causes various problems in disease pathologies through disruption of permeability regulation [17, 18] . Vestaine A 1 suppresses VEGF-induced vascular permeability ( Fig. 5A and 5B), suggesting that vestaine A 1 could normalize the abnormal vessels induced by excess VEGF and enhance vascular maturation. Sphingosine 1-phosphate (S1P), the lipid mediator derived from sphingolipid, is a well-known vascular maturation factor. S1P plays a role in promoting angiogenesis and enhancing vascular maturation via its receptor S1PRs, especially via S1P 1 [22] . Using in vitro and in vivo models, it has been reported that S1P and S1P 1 agonists promote endothelial survival and angiogenesis by activating both the ERK and Akt pathways [23, 24] and reverse endothelial permeability induced by growth factors, LPS, and ischemia-induced injury [25] [26] [27] [28] . The similarities between vestaine A 1 and S1P 1 agonists in their biological functions and activated pathways further support that vestaine A 1 would function as both a pro-angiogenic and vessel maturation factor. Although we didn't detect any S1P 1 agonistic activity of vestaine A 1 (unpublished data), it would be intriguing to evaluate crosstalk among the vestaine A 1 pathway and S1P 1 signaling.
As discussed above, the determination of a target molecule of vestaine A 1 is critical to understanding the mechanism of action. So far we do not have many clues to find the target. One interesting structural property of vestaines is betaine structure. Betaine is a neutral chemical compound both with the positively charged part and with the negatively charged part in the same molecule. Trimethylglycine is a typical biological compound having a betaine structure, and it has been known that betaine is involved in methylation reactions and detoxification of homocysteine. Homocysteine is harmful for vessels since it inhibits angiogenesis by preventing proliferation and migration of endothelial cells [29, 30] . Trimethylglycine is known to scavenge the harmful effect following homocysteine using methyl groups to afford methionine [31, 32] . Thus, we expected that the betaine portion of vestaine A 1 might work in the same manner as that of trimethylglycine and exert its effect on endothelial cells. However, trimethylglycine, homocysteine, and N-acethyl-L-cysteine methyl ester showed no effect either alone or in combination with vestaine A 1 in the VS-G assay (unpublished data), which suggests that vestaine A 1 provides a protective effect to endothelial cells through a different mechanism from trimethylglycine. Additionally, to elucidate which is an active body, vestaine A 1 or its metabolites, we evaluated the derivatives of vestaine A 1 . Table 1 showed that vestaine A 1 itself is an active body and all of the components of vestaine A 1 is necessary for its activity. Further examination would be needed to reveal the molecular pathway of vestaine A 1 .
One of the physiologically important effects of vestaine A 1 is suppression of vascular permeability. There are many diseases associated with elevation in vascular permeability. For example, in the lesions of patients suffering from retinopathy, brain hemorrhage, and cancer, bleeding and hypoxia induced by immature and fragile vessels cause disease progression and resistance to therapy. Additionally, in acute respiratory distress syndrome/acute lung injury (ARDS/ALI), the leakage from pulmonary vessels induced by inflammatory cytokines impairs lung functions [33] . Recently, it has been reported that inhibiting agents for vascular permeability are effective for the treatment in animal models. Peng et al. have indicated that S1P and SEW-2871, a selective S1P 1 agonist, decreased pulmonary endothelial leakage in murine and canine LPS models, which are generally used as an ASDS/ALI model [26, 22, [34] [35] [36] [37] 25] . These findings suggest that enhancement of vascular integrity may be effective for suppression of vascular leakage. Thus, it would be meaningful to explore the possibility to utilize vestaine A 1 for therapeutic treatment as an inhibitor of vascular permeability in a pathological condition. Further investigation of vestaine A 1 in a disease model relating to increased permeability would be important.
In conclusion, the present study revealed that vestaine A 1 is a unique novel compound with both pro-angiogenic and anti-vascular permeability activity. Although the mechanism of vestaine A 1 action remains to be elucidated, we speculate that identification of unknown target molecules and the pathway of vestaine A 1 for regulating endothelial functions may provide useful insight into vascular biology and also lead to a new therapy for abnormal vascular permeability-related diseases.
